Fidan Yeliz, Muçaj Stela, Timur Selin Seda, Gürsoy R Neslihan
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.
J Liposome Res. 2024 Jun;34(2):316-334. doi: 10.1080/08982104.2023.2268710. Epub 2023 Oct 17.
Nano-drug delivery systems have opened new pathways for tumor treatment by overcoming some of the limitations of conventional drugs, such as physiological degradation, short half-life, and rapid release. Liposomes are promising nanocarrier systems due to their biocompatibility, low toxicity, and high inclusivity, as well as their enhanced drug bioavailability. Various strategies for active targeting of liposomal formulations have been investigated to achieve the highest drug efficacy. This review aims to summarize current developments in novel liposomal formulations, particularly ligand-targeted liposomes (such as folate, transferrin, hyaluronic acid, antibodies, aptamer, and peptide, etc.) used for the therapy of various cancers and provide an insight on the challenges and future of liposomes for scientists and pharmaceutical companies.
纳米药物递送系统通过克服传统药物的一些局限性，如生理降解、半衰期短和快速释放等，为肿瘤治疗开辟了新途径。脂质体因其生物相容性、低毒性、高包容性以及增强的药物生物利用度，是很有前景的纳米载体系统。为了实现最高的药物疗效，人们研究了各种脂质体制剂的主动靶向策略。这篇综述旨在总结新型脂质体制剂的当前进展，特别是用于治疗各种癌症的配体靶向脂质体（如叶酸、转铁蛋白、透明质酸、抗体、适体和肽等），并为科学家和制药公司提供有关脂质体面临的挑战和未来发展的见解。
